Skip to Main Content

Paper Details

Cost-effectiveness for KTE-X19 CAR T therapy for adult patients with relapsed/refractory mantle cell lymphoma in the United States.
J Med Econ
13
2021
Author NameAffiliation
Bijal ShahMoffitt Cancer Center
  • 1 - 1

Datasets

Release 1.2